SCHEMBL5543115

SCHEMBL5543115

[CH2]Cc1nnnn1-c1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
HTT P42858 4/20 0.51
LMNA P02545 3/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
ALDH1A1 P00352 7/20 0.48
MAPT P10636 2/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
NOTUM Q6P988 2/20 0.42
CNKSR1 Q969H4 1/20 0.41
PKM P14618 1/20 0.41
NLRP3 Q96P20 1/20 0.41
FLT3 P36888 1/20 0.40
HSD11B1 P28845 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HPGD P15428 1/20 0.39
CCR6 P51684 1/20 0.39
NLRP1 Q9C000 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25250741 0.84 LMNA (0.54) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5546454 0.81 POLB (0.44) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5544572 0.81 ALDH1A1 (0.47) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5546774 0.80 CYP1A2 (0.56) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5545310 0.80 HTT (0.60) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL27610352 0.79 POLB (0.52) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL29417975 0.79 LMNA (0.52) POLBHTTLMNAL3MBTL1MAPT
SCHEMBL25213643 0.79 LMNA (0.52) POLBHTTLMNAL3MBTL1MAPT
SCHEMBL5543968 0.76 POLB (0.48) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5543973 0.76 POLB (0.45) POLBHTTLMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885HTT 4644/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.